Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00492 (
hypoxanthine-guanine phosphoribosyltransferase
)
2,385
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Crude extracts of the oocysts of Eimeria tenella, a protozoan parasite of the coccidium family that develops inside the caecal epithelial cells of infected chickens, do not incorporate glycine or formate into purine nucleotides; this suggests lack of capability for de novo purine synthesis by the parasite. The extracts, however, contain high levels of activity of the purine salvage enzymes: hypoxanthine, guanine, xanthine, and adenine phosphoribosyltransferases and adenosine kinase. The absence of AMP deaminase from the parasite indicates that E. tenella cannot convert AMP to
GMP
; the latter thus has to be supplied by the hypoxanthine, xanthine, or guanine phosphoribosyltransferase of the parasite. These three activities are associated with one enzyme (HXGPRTase), which has been purified to near homogeneity in high yield (71-80%) in a single step by
GMP
-agarose affinity column chromatography. The size of the enzyme subunit is estimated to be 23,000 daltons by NaDodSO4 gel electrophoresis. Kinetic studies suggest differences in purine substrate specificity between E. tenella HXGPRTase and chicken liver
HGPRTase
. Allopurinol preferentially inhibits the parasite enzyme by competing with hypoxanthine; a Ki approximately 22 microM.
...
PMID:Purine metabolism in the protozoan parasite Eimeria tenella. 627 76
Acyclovir [9-(2-hydroxyethoxymethyl)guanine], a clinically useful anti-herpesvirus agent, was a weak inhibitor (Ki = 190 microM) of
hypoxanthine-guanine phosphoribosyltransferase
(
HGPRTase
) from human erythrocytes. Nevertheless, this acyclic nucleoside analog was a more effective inhibitor than were its natural counterparts, guanosine (Ki = 1400 microM) and deoxyguanosine (Ki = 570 microM). The two oxidized metabolites of acyclovir, 9-carboxymethoxymethylguanine (Ki = 720 microM) and 8-hydroxy-9-(2-hydroxyethoxymethyl)guanine (Ki greater than 2000 microM), were less inhibitory than was the parent drug. None of the phosphorylated metabolites of acyclovir was as potent an inhibitor of
HGPRTase
as was
GMP
(Ki = 4 microM). However, the Ki value for acyclovir monophosphate was similar to that of dGMP (12 microM). The Ki values for acyclovir diphosphate (8.3 microM) and triphosphate (30 microM) were less than those for dGDP (110 microM) and dGTP (140 microM). The levels of these phosphate esters of acyclovir in cultured monkey kidney (Vero) and human embryo fibroblast (WI38) cells exposed to therapeutic levels of the drug were well below the observed Ki values. However, in herpesvirus-infected WI38 cells the levels of the phosphate esters of acyclovir were high enough potentially to inhibit the enzyme. Although inhibition of this enzyme by the phosphorylated metabolites of acyclovir may occur in these infected cells, concentrations of the drug very much higher than the EC50 concentration were required to achieve inhibitory levels. It is, therefore, unlikely that this inhibition contributes significantly to the antiviral activity.
...
PMID:Effects of acyclovir and its metabolites on hypoxanthine-guanine phosphoribosyltransferase. 663 69
An assay procedure, utilizing high pressure liquid chromatography, has been designed which allows both reactions catalyzed by
hypoxanthine-guanine phosphoribosyltransferase
to be monitored simultaneously. Using this procedure and the theories described by Huang (Huang, C. V. (1979) Methods. Enzymol. 63, 486-500) for alternate substrate kinetic analysis, we have determined that purified
hypoxanthine-guanine phosphoribosyltransferase
from yeast catalyzes the formations of both IMP and
GMP
through the use of an Ordered Bi Bi kinetic mechanism, and that guanine is highly preferred over hypoxanthine as substrate in the forward reaction. This proposed kinetic mechanism has been confirmed using flow dialysis experiments in which a binary enzyme-5-phosphoribosyl-alpha-1-pyrophosphate complex was characterized but where enzymic complexes, with either guanine or hypoxanthine, were not detected. Also consistent with this kinetic mechanism was our observation that an exchange of label between [14C]guanine or [14C]hypoxanthine and their respective nucleotides (
GMP
and IMP) was not catalyzed by
hypoxanthine-guanine phosphoribosyltransferase
. However, a significant exchange of label between [32P]pyrophosphate and 5-phosphoribosyl-alpha-1-pyrophosphate is observed upon incubation with this enzyme, suggesting that
hypoxanthine-guanine phosphoribosyltransferase
may exist, in part, as a phosphoribosyl-enzyme complex in the presence of 5-phosphoribosyl-alpha-1-pyrophosphate.
...
PMID:Studies of the kinetic mechanism of hypoxanthine-guanine phosphoribosyltransferase from yeast. 703 45
Xanthine phosphoribosyltransferase (XPRTase; EC 2.4.4.22) was found in the promastigotes of four species of Leishmania (L. mexicana, L. donovani, L. braziliensis and L. tarentolae). In no case was there any transribosylation from 5-phosphoribosyl-1-pyrophosphate (PRibPP), forming XMP, in dialyzed preparations, unless activated by a divalent cation. Magnesium and zinc were very low in activation efficiency in all cases, while manganese was optimally efficient. Cobalt was essentially equal to manganese for activation of the enzyme from L. mexicana and L. braziliensis but much less efficient for the enzyme from L. donovani and L. tarentolae. Gel filtration profiles of cell extracts of L. mexicana on Sephadex G-200 indicated that the enzymes catalyzing the transribosylation from PRibPP to guanine, hypoxanthine, and xanthine were inseparable. All were eluted near the void volume. The enzyme for adenine transribosylation was clearly separate. When cell extracts of L. mexicana were applied to Sephadex G-100 columns, the activity toward XMP formation from xanthine eluted with the void volume, together with a portion of that for the formation of
GMP
and IMP from guanine and hypoxanthine. A second peak of
HGPRTase
(EC 2.4.2.8) eluted somewhat later and was devoid of XPRTase activity. XPRTase from promastigotes of L. mexicana is heat labile, has rather a broad pH optima, and is stable to freezing when protected by nonspecific cell protein (40,000 g supernate as opposed to 100,000 g supernates).
...
PMID:Xanthine phosphoribosyltransferase in Leishmania: divalent cation activation. 713 52
Erythrocyte
hypoxanthine-guanine phosphoribosyltransferase
has been highly purified from five unrelated patients with a deficiency of this enzyme. Affinity chromatography using either
GMP
-Sepharose or an immunoadsorbent was the most productive step in the purifications. The specific activity of the purified enzyme was unchanged for patients L. P. and G. S., and slightly decreased for patient R. H., as compared to control subjects. Enzyme from patient I. V. and from patient E. S. exhibited markedly reduced specific activities when purified to near homogeneity. The level of immunoreactive protein in patient I. V. appeared to be significantly higher than normal. The apparent subunit molecular weight of the enzyme from patient G. S. was decreased by approximately 1000 while it was increased by approximately 400 from patient I. V. The isoelectric points of the subunit isozymes were shifted to higher pH values from patients I. V. and E. S., and to lower pH values from patient L. P.; the subunit isozymes from patient G. S. were identical with normal. These studies provide direct evidence for the existence of at least four different mutations in the structural gene for
hypoxanthine-guanine phosphoribosyltransferase
. The four different mutant forms of human
hypoxanthine-guanine phosphoribosyltransferase
that have been identified are named as follows: patient L. P., HPRTToronto; patient G. S., HPRTLondon; patient E. S., HPRTKinston; and patient I. V., HPRTMunich.
...
PMID:Human hypoxanthine-guanine phosphoribosyltransferase. Purification and characterization of mutant forms of the enzyme. 728 14
Hypoxanthine-guanine phosphoribosyltransferase
(EC 2.4.2.8) from beef brain has been purified 3100-fold to apparent homogeneity using a purification procedure based on
GMP
-Sepharose affinity chromatography. The native enzyme has a molecular weight of 84,000 as determined by gel filtration studies. A subunit molecular weight of 26,000 was obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, suggesting that the enzyme is a trimer. Two forms of the enzyme have been separated by nondenaturing polyacrylamide gel electrophoresis and isoelectric focusing. Basic pI values of 7.85 and 8.10 were obtained for the two forms. These values are much higher than have been observed with any other purified phosphoribosyltransferase. The amino acid composition of the enzyme is 18 Lys, 6 His, 9 Arg, 1 Trp, 6 Cys, 28 Asx, 12 Thr, 16 Ser, 19 Glx, 10 Pro, 23 Gly, 16 Ala, 17 Val, 5 Met, 11 Ile, 19 Leu, 9 Tyr, and 8 Phe. An unusual basic amino acid, yet to be identified, was also present. The enzyme exhibits Km values of 0.42 microM for guanine, 0.99 microM for hypoxanthine, 18.6 microM for P-Rib-PP in the presence of guanine, and 2.9 microM for P-Rib-PP in the presence of hypoxanthine.
...
PMID:Studies of an unusually basic hypoxanthine-guanine phosphoribosyltransferase. 735 77
The
hypoxanthine-guanine phosphoribosyltransferase
(
HGPRTase
) of human and the parasitic trematode, Schistosoma mansoni, were expressed at high levels in transformed Escherichia coli in their native forms. Guanosine 2',3'-dialdehyde 5'-phosphate (ox-
GMP
) was shown to bind irreversibly to both enzymes in a time-dependent manner. This binding was stabilized by sodium borohydride reduction, suggesting that a Schiff's base is formed between the dialdehyde groups of ox-
GMP
and the amino group of a lysine residue in the enzymes. This linkage formation applies also to inosine 2',3'-dialdehyde 5'-phosphate but not to adenosine 2',3'-dialdehyde 5'-phosphate.
GMP
was found to be protective against ox-
GMP
inactivation and [3H]ox-
GMP
labeling of both HGPRTases. 5-Phosphoribosyl-1-diphosphate (PRibPP) also protects human
HGPRTase
against the ox-
GMP
inactivation and [3H]ox-
GMP
labeling but provides virtually no protection against the ox-
GMP
inactivation and labeling of the schistosomal enzyme, even though PRibPP binds to the latter with a threefold higher affinity. These results imply that PRibPP and ox-
GMP
compete with each other for binding to the human
HGPRTase
but not for binding to the schistosomal enzyme. This discrepancy could be exploited for the purpose of designing selective inhibitors of the schistosomal
HGPRTase
. Guanosine 2',3'-dialdehyde (ox-guanosine) is nearly as active as ox-
GMP
in inhibiting schistosomal
HGPRTase
but much less potent in inhibiting human
HGPRTase
, suggesting that ox-guanosine and ox-
GMP
may bind equally well to the parasite enzyme. PRibPP can protect human but not schistosomal
HGPRTase
against the inactivation by ox-guanosine. Therefore, ox-
GMP
and ox-guanosine must be forming Schiff's bases with the same amino acid residues in each of the two HGPRTases.
...
PMID:Differential inhibitory effects of GMP-2',3'-dialdehyde on human and schistosomal hypoxanthine-guanine phosphoribosyltransferases. 751 83
Labeling of human and schistosomal hypoxanthine-guanine phosphoribosyltransferases (HGPRTases) with
GMP
-2',3'-dialdehyde (ox-
GMP
) results in nearly complete inactivation of the enzymes. Digestion of the [3H]ox-
GMP
-modified HGPRTases with trypsin followed by high-performance liquid chromatographic fractionation, partial amino acid sequencing, and mass spectral analysis of the labeled peptides revealed that four peptides from each of the two HGPRTases were labeled with ox-
GMP
. The conclusion from these studies indicates that two segments of the human enzyme protein, Ser 4-Arg 47 and Ser 91-Arg 100, and one region in the schistosomal enzyme, Gly 95-Lys 133, were labeled by ox-
GMP
. Since the ox-
GMP
labeling of human
HGPRTase
was effectively blocked by either
GMP
or PRibPP, whereas that of schistosomal
HGPRTase
was inhibited only by
GMP
[Kanaaneh, J., Craig, S. P., III, & Wang, C. C. (1994) Eur. J. Biochem. 223, 595-601], the two labeled peptides in human enzyme may be involved in binding to both
GMP
and PRibPP while the one peptide in schistosomal enzyme may be implicated only in
GMP
binding. We have also confirmed a previous observation [Keough, D. T., Emmerson, B. T., & de Jersey, J. (1991) Biochim. Biophys. Acta 1096, 95-100] that carboxymethylation of Cys 22 in the human
HGPRTase
by iodoacetate was inhibited by PRibPP. We also demonstrated that the carboxymethylation of Cys 25 in schistosomal
HGPRTase
by iodoacetate was specifically blocked by PRibPP. Apparently, the N-terminal regions in both enzymes are involved in PRibPP binding. The fact that ox-
GMP
labels the N-terminal region in human enzyme but not in schistosomal enzyme and that PRibPP protects against ox-
GMP
labeling in human enzyme but not in schistosomal enzyme both suggest that the amino-terminal PRibPP-binding site may be in close proximity to the
GMP
-binding site in human
HGPRTase
but not in schistosomal
HGPRTase
. This clear distinction between the active sites of human and schistosomal HGPRTases could be further exploited for potential opportunities for antischistosomal chemotherapy.
...
PMID:Identification of the active sites of human and schistosomal hypoxanthine-guanine phosphoribosyltransferases by GMP-2',3'-dialdehyde affinity labeling. 757 12
The metabolic fate of labeled guanine and of prelabeled guanine nucleotides (GuRN) was studied in cultured rat cardiomyocytes. Special attention was given to guanine salvage in comparison to degradation; to the contribution of GuRN to adenine nucleotides (AdRN); to the fluxes from
GMP
to IMP and from IMP to
GMP
; and to the degradation pathways of GuRN. In accordance with the 3- to 4-fold higher activity of guanine deaminase (guanase), in comparison to that of
hypoxanthine-guanine phosphoribosyltransferase
(
HGPRT
), the rate of guanine deamination to xanthine exceeded that of guanine incorporation into nucleotides (at 4 microM) by 13.2-fold. The label from guanine incorporated into nucleotides was found mainly (81%) in GuRN, but also in IMP and AdRN. The prelabeled GuRN lost 43% of the label in 4 h, reflecting mainly degradation to xanthine (and uric acid) and synthesis of nucleic acids. Blocking nucleoside degradation was associated with a marked accumulation of label in guanosine and inosine (guanosine/inosine labeling ratio is 1.25). The results indicate that in the myocardium guanine is a poor substrate for salvage synthesis of GuRN and that its contribution to the homeostasis of adenine nucleotides is negligible; that
GMP
degradation to xanthine proceeds through both guanosine and IMP; and that the cardiomyocytes contain the activity of GMP reductase and of the enzymes converting IMP to
GMP
.
...
PMID:Metabolism of guanine and guanine nucleotides in primary rat cardiomyocyte cultures. 758 72
The success of chemotherapy of colon tumours is currently limited. We have therefore used the human colon tumour cell line HT-29 to evaluate the cytotoxic effects of various drug combinations. Trimidox (3,4,5-trihydroxybenzamidoxime), a recently patented inhibitor of ribonucleotide reductase was combined with cytosinearabinoside (Ara-C) or 2',2'-difluorodeoxycytidine (DFDC) in order to inhibit both pyrimidine de novo and salvage pathways. Synergistic cytotoxic effects were observed. When HT-29 cells were sequentially treated with trimidox (20 microM for 24 h) and Ara-C (2 microM for 2 h), colony numbers decreased to 71% of the value calculated for additive cytotoxicity. When cells were simultaneously treated with trimidox (10 microM and 15 microM) and DFDC (0.2 nM), synergistic inhibition of colony formation was likewise noted (colony numbers decreased to values as low as 73% or 71% of the values calculated for additive cytotoxicity). On the other hand, we combined tiazofurin, an inhibitor of the
guanylate
de novo pathway, with allopurinol, which inhibits the
guanylate
salvage pathway by increasing intracellular hypoxanthine concentrations, leading to inhibition of the enzyme
hypoxanthine-guanine phosphoribosyltransferase
(
HGPRT
). Synergistic cytotoxic effects were observed under these conditions too. When cells were treated with 10 microM tiazofurin and 400 microM or 800 microM allopurinol the number of colonies decreased to 69% and 27%, respectively, of the values calculated for additive effects. Our data suggest these drug combinations to be promising options in the treatment of human colon cancer.
...
PMID:[Synergistic cytotoxic effects of chemotherapy in colon tumor cells by simultaneous inhibition of de novo and salvage energy metabolism pathways]. 794 93
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>